VYGR Valuation

Voyager Therapeutics Inc

Add to Watchlist

Advanced Chart

3.200

-0.07(-2.141%)1D

Overview
Forecast
Valuation
Earnings

VYGR Relative Valuation

VYGR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VYGR is overvalued; if below, it's undervalued.

Historical Valuation

Voyager Therapeutics Inc (VYGR) is now in the Fair zone, suggesting that its current forward PS ratio of 4.67 is considered Fairly compared with the five-year average of -3.20. The fair price of Voyager Therapeutics Inc (VYGR) is between 2.60 to 4.79 according to relative valuation methord.

Relative Value

Fair Zone

2.60-4.79

Current Price：3.20

Fair

-1.52

Trailing

Forward

0.65

EV/EBITDA

Voyager Therapeutics Inc. (VYGR) has a current EV/EBITDA of 0.65. The 5-year average EV/EBITDA is -1.31. The thresholds are as follows: Strongly Undervalued below -10.80, Undervalued between -10.80 and -6.06, Fairly Valued between 3.43 and -6.06, Overvalued between 3.43 and 8.17, and Strongly Overvalued above 8.17. The current Forward EV/EBITDA of 0.65 falls within the Historic Trend Line -Fairly Valued range.

0.52

EV/EBIT

Voyager Therapeutics Inc. (VYGR) has a current EV/EBIT of 0.52. The 5-year average EV/EBIT is 4.68. The thresholds are as follows: Strongly Undervalued below -43.58, Undervalued between -43.58 and -19.45, Fairly Valued between 28.81 and -19.45, Overvalued between 28.81 and 52.94, and Strongly Overvalued above 52.94. The current Forward EV/EBIT of 0.52 falls within the Historic Trend Line -Fairly Valued range.

4.67

Voyager Therapeutics Inc. (VYGR) has a current PS of 4.67. The 5-year average PS is 10.83. The thresholds are as follows: Strongly Undervalued below -16.69, Undervalued between -16.69 and -2.93, Fairly Valued between 24.58 and -2.93, Overvalued between 24.58 and 38.34, and Strongly Overvalued above 38.34. The current Forward PS of 4.67 falls within the Historic Trend Line -Fairly Valued range.

-1.46

P/OCF

Voyager Therapeutics Inc. (VYGR) has a current P/OCF of -1.46. The 5-year average P/OCF is -4.58. The thresholds are as follows: Strongly Undervalued below -14.32, Undervalued between -14.32 and -9.45, Fairly Valued between 0.28 and -9.45, Overvalued between 0.28 and 5.15, and Strongly Overvalued above 5.15. The current Forward P/OCF of -1.46 falls within the Historic Trend Line -Fairly Valued range.

-1.41

P/FCF

Voyager Therapeutics Inc. (VYGR) has a current P/FCF of -1.41. The 5-year average P/FCF is -3.03. The thresholds are as follows: Strongly Undervalued below -22.56, Undervalued between -22.56 and -12.79, Fairly Valued between 6.74 and -12.79, Overvalued between 6.74 and 16.51, and Strongly Overvalued above 16.51. The current Forward P/FCF of -1.41 falls within the Historic Trend Line -Fairly Valued range.

Voyager Therapeutics Inc (VYGR) has a current Price-to-Book (P/B) ratio of 0.66. Compared to its 3-year average P/B ratio of 1.96 , the current P/B ratio is approximately -66.21% higher. Relative to its 5-year average P/B ratio of 2.07, the current P/B ratio is about -68.05% higher. Voyager Therapeutics Inc (VYGR) has a Forward Free Cash Flow (FCF) yield of approximately -63.59%. Compared to its 3-year average FCF yield of 0.22%, the current FCF yield is approximately -29423.89% lower. Relative to its 5-year average FCF yield of -17.24% , the current FCF yield is about 268.93% lower.

0.66

P/B

Median3y

1.96

Median5y

2.07

-63.59

FCF Yield

Median3y

0.22

Median5y

-17.24

Competitors Valuation Multiple

The average P/S ratio for VYGR's competitors is 4.24, providing a benchmark for relative valuation. Voyager Therapeutics Inc Corp (VYGR) exhibits a P/S ratio of 4.67, which is 10.00% above the industry average. Given its robust revenue growth of -66.83%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VYGR.O

Voyager Therapeutics Inc

Galectin Therapeutics Inc

Loss

208.86M

CBIO.O

Crescent Biopharma Inc

Loss

170.88M

KYTX.O

Kyverna Therapeutics Inc

Performance Decomposition

Market capitalization of VYGR decreased by 65.18% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -58.05 to -479.24.

The secondary factor is the Revenue Growth, contributed -66.83%to the performance.

Overall, the performance of VYGR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-66.83%

19.52M → 6.47M

Revenue Growth

725.56%

-58.05 → -479.24

Margin Expansion

-723.91%

0.36 → -2.24

P/E Change

-65.18%